Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends / Edoardo Fabini, Elisabetta Manoni, Claudia Ferroni, Alberto Del Rio, Manuela Bartolini
Lysine methyltransferases SMYD2 and SMYD3 are involved in the epigenetic regulation of cell differentiation and functioning. Overexpression and deregulation of these enzymes have been correlated to the insurgence and progression of different tumors, making them promising molecular targets in cancer therapy even if their role in tumors is not yet fully understood. In this light, selective small-molecule inhibitors are required to fully understand and validate these enzymes, as this is a prerequisite for the development of successful targeted therapeutic strategies. The present review gives a systematic overview of the chemical probes developed to selectively target SMYD2 and SMYD3, with particular focus on the structural features important for high inhibitory activity, on the mode of inhibition and on the efficacy in cell-based and inin vivomodels. in vivo.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Future medicinal chemistry - 11(2019), 08, Seite 901- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fabini, Edoardo [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (21 p) |
|---|
| doi: |
10.4155/fmc-2018-0380 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL001069306 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL001069306 | ||
| 003 | DE-627 | ||
| 005 | 20230430081614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210608s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/fmc-2018-0380 |2 doi | |
| 035 | |a (DE-627)KFL001069306 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/fmc-2018-0380 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Fabini, Edoardo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends |c Edoardo Fabini, Elisabetta Manoni, Claudia Ferroni, Alberto Del Rio, Manuela Bartolini |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (21 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Lysine methyltransferases SMYD2 and SMYD3 are involved in the epigenetic regulation of cell differentiation and functioning. Overexpression and deregulation of these enzymes have been correlated to the insurgence and progression of different tumors, making them promising molecular targets in cancer therapy even if their role in tumors is not yet fully understood. In this light, selective small-molecule inhibitors are required to fully understand and validate these enzymes, as this is a prerequisite for the development of successful targeted therapeutic strategies. The present review gives a systematic overview of the chemical probes developed to selectively target SMYD2 and SMYD3, with particular focus on the structural features important for high inhibitory activity, on the mode of inhibition and on the efficacy in cell-based and inin vivomodels. in vivo | ||
| 700 | 1 | |a Manoni, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Ferroni, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Rio, Alberto Del |e verfasserin |4 aut | |
| 700 | 1 | |a Bartolini, Manuela |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future medicinal chemistry |d London : Future Science, 2009 |g 11(2019), 08, Seite 901- |h Online-Ressource |w (DE-627)KFL000006157 |w (DE-600)2572258-X |w (DE-576)398101442 |x 1756-8927 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:08 |g pages:901- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/fmc-2018-0380 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 08 |h 901- | ||